Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Innoviva, Inc. - Common Stock (NQ:INVA)

23.85 +1.15 (+5.07%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 17, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Innoviva, Inc. - Common Stock

< Previous 1 2 3 Next >
Innoviva Inc (NASDAQ:INVA) Presents a Compelling Value Investment Case ↗
Via Chartmill
News headline image
Biotech Is Heating Up—These 2 Red-Hot Stocks Stand Out ↗
Via MarketBeat
News headline image
Get insights into the top gainers and losers of Tuesday's after-hours session. ↗
Let's have a look at what is happening on the US markets after the closing bell on Tuesday. Below you can find the top gainers and losers in today's after hours session. 
Via Chartmill
News headline image
Stay updated with the stocks that are on the move in today's pre-market session. ↗
The US market session of Thursday has yet to be opened, let's have a look at the top gainers and losers in the pre-market session today. 
Via Chartmill
News headline image
Beyond The Numbers: 5 Analysts Discuss Innoviva Stock ↗
 
Via Benzinga
News headline image
A Look Into Healthcare Sector Value Stocks ↗
 
Via Benzinga
News headline image
Value Investing Case Study: INNOVIVA INC (NASDAQ:INVA) ↗
Discover Innoviva (INVA), a potential value stock with strong fundamentals. Its attractive valuation, healthy balance sheet, and solid profitability suggest it trades below intrinsic worth. 
Via Chartmill
News headline image
Innoviva Inc (NASDAQ:INVA): A Prime Candidate for Value Investors Seeking Undervalued Stocks ↗
Discover Innoviva (INVA), a value stock with strong fundamentals. It trades below intrinsic value, boasts a healthy balance sheet, and has promising growth prospects in biopharma. 
Via Chartmill
News headline image
Innoviva Inc (NASDAQ:INVA) Recognized as a "Decent Value" Stock with Strong Valuation and Growth Potential ↗
Innoviva (INVA) is a value stock with strong valuation metrics, solid financial health, and growth potential, making it an attractive pick for value investors. 
Via Chartmill
News headline image
Expert Outlook: Innoviva Through The Eyes Of 4 Analysts ↗
 
Via Benzinga
News headline image
This Arm Holdings Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Monday ↗
 
Via Benzinga
News headline image
Innoviva (INVA) Q2 Sales Jump 64% ↗
Via The Motley Fool
News headline image
This Cisco Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday ↗
 
Via Benzinga
News headline image
Rep. George Whitesides Has Sold Up to $5.18M Worth Of Innoviva Stock: Here's What You Should Know ↗
 
Via Benzinga
News headline image
Excelerate Energy, MediaAlpha And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
US Stock: Innoviva ↗
Innoviva Incorporated is a healthcare focused asset management company. The Company intends to participate in the development, commercialization, and financial management of bio-pharmaceuticals. 
Via Talk Markets
Topics Stocks / Equities
News headline image
INVA Stock Earnings: Innoviva Misses EPS, Beats Revenue for Q2 2024 ↗
INVA stock results show that Innoviva missed analyst estimates for earnings per share but beat on revenue for the second quarter of 2024. 
Via InvestorPlace
News headline image
The 3 Most Undervalued Under-$50 Stocks to Buy in July 2024 ↗
A full-throated bull market makes it tough to find undervalued stocks under $50, but these three could soon lead the charge higher. 
Via InvestorPlace
News headline image
3 Once-in-a-Lifetime Stock Picks Due for an Unprecedented Surge ↗
Discover three high-growth stock picks set for unprecedented surges in the metals, marine transportation, and pharmaceutical industries. 
Via InvestorPlace
News headline image
Analyst Projects Strong Growth for GSK-Innoviva Partnered Respiratory Drugs ↗
Discover Cantor Fitzgerald's analysis on Innoviva, highlighting its unique royalty-based business model with GSK for asthma and COPD products. 
Via Benzinga
News headline image
3 Under-$20 Stocks That Could Make You a Fortune ↗
Discover three under-$20 stocks that could make a fortune in the pharmaceuticals, entertainment, and application software industries. 
Via InvestorPlace
News headline image
INVA Stock Earnings: Innoviva Beats EPS, Beats Revenue for Q1 2024 ↗
INVA stock results show that Innoviva beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
News headline image
5 Value Stocks In The Healthcare Sector ↗
 
Via Benzinga
News headline image
If You Can Only Buy One Biotech Stock in January, It Better Be One of These 3 Names ↗
Biotech is one of the areas of interest in the market today, adding a biotech stock could be huge play this month. 
Via InvestorPlace
News headline image
Chart Of The Day: Innoviva - Individual Investor Favorite ↗
100% technical buy signals 14 new highs and up 12.87% in the last month 36.40+ Weighted Alpha 
Via Talk Markets
News headline image
A Look Into Healthcare Sector Value Stocks ↗
 
Via Benzinga
News headline image
Overview Of Value Stocks In The Healthcare Sector ↗
 
Via Benzinga
News headline image
Why These 7 Stocks Are the Best Ways to Play Biotech Right Now ↗
With biotech stocks offering myriad viable opportunities irrespective of broader conditions, this sector is worth a closer look. 
Via InvestorPlace
News headline image
AstraZeneca-Spin Off Entasis Secures FDA Approval For First Pathogen-Targeted Therapy Addressing Acinetobacter ↗
 
Via Benzinga
News headline image
Over $125M Bet On Occidental Petroleum? Check Out These 4 Stocks Insiders Are Buying ↗
Although US stocks closed higher on Monday, there were a few notable insider trades. 
Via Benzinga
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.